LUTETHIM-177 PSMA: A Radiopharmaceutical That Increases the Chance of Prostate Cancer Cure
Today, for cancer cells in patients with stage 4 prostate cancer that have already masticated to other organs (such as lymph nodes further distant from the prostate, bones, or liver) which are resistant to hormone therapy, although the cancer at this stage cannot be completely cured, Lutetium-177 PSMA (Lu-177 labeled PSMA-targeted radioligand therapy) in combination with regular cancer treatment can slow down the cancer’s progression (imaged-based, progress-free survival) and prolong the overall survival.
Knock Out Thyroid Cancer with I-131 Radiotherapy
Thyroid Cancer is more typical in women than men. Often, patients can identify the symptom when they discover a lump in their neck.